“The initiative is a key step in positioning India as a leader in the clinical development of pharmaceutical agents,” said the Ministry of Health and Family Welfare. ICMR has formalized Memorandums of Agreement (MoAs) with several sponsors for four promising molecules under its Phase 1 clinical trials network.
The studies, published in the journal Blood, suggest that the mRNA Covid-19 vaccine may have reduced efficacy in people with chronic lymphocytic leukemia (CLL) and multiple myeloma, two types of blood cancer
